A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

PHASE2RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

April 16, 2025

Primary Completion Date

January 8, 2029

Study Completion Date

January 8, 2029

Conditions
Multiple Sclerosis
Interventions
BIOLOGICAL

mRNA-1195

IM injection

BIOLOGICAL

Placebo

IM injection

Trial Locations (16)

48334

RECRUITING

Quest Research Institute, Farmington Hills

63110

RECRUITING

Washington University School of Medicine Neurology Clinical Unit, St Louis

73104

RECRUITING

Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence, Oklahoma City

75024

RECRUITING

Saturn Research Solutions, Plano

79912

RECRUITING

ANESC Research, El Paso

02131

RECRUITING

Boston Clinical Trials Inc - Internal Medicine, Boston

75390-8806

RECRUITING

University of Texas Southwestern Medical Center, Dallas

04575

RECRUITING

University of the Sunshine Coast Clinical Trials, Birtinya

BS10 5NB

RECRUITING

North Bristol NHS Trust - Southmead Hospital, Bristol

CF14 4XW

RECRUITING

Cardiff and Vale University Health Board - University Hospital Wales, Cardiff

EH16 4SB

RECRUITING

Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh

G51 4TF

RECRUITING

NHS Greater Glasgow & Clyde - Institute of Neurological Sciences, Glasgow

CB2 0SL

RECRUITING

Cambridge Clinical Research Centre, London

CT1 3NG

RECRUITING

East Kent Hospitals University NHS Foundation Trust, London

NE14LP

RECRUITING

The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne

S10 2JF

RECRUITING

Sheffield Teaching Hospital NHS foundation Trust, Herries Road, Sheffield

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY